These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 12584269)

  • 1. Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat.
    Nielsen FT; Ottosen P; Starklint H; Dieperink H
    Nephrol Dial Transplant; 2003 Mar; 18(3):491-6. PubMed ID: 12584269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats.
    Lloberas N; Torras J; Alperovich G; Cruzado JM; Giménez-Bonafé P; Herrero-Fresneda I; Franquesa Ml; Rama I; Grinyó JM
    Nephrol Dial Transplant; 2008 Oct; 23(10):3111-9. PubMed ID: 18469305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired glomerular and tubular function as a short-term effect of sirolimus treatment in the rat.
    Nielsen FT; Starklint H; Dieperink H
    Am J Nephrol; 2005; 25(4):411-6. PubMed ID: 16088082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood.
    Barten MJ; Streit F; Boeger M; Dhein S; Tarnok A; Shipkova M; Armstrong VW; Mohr FW; Oellerich M; Gummert JF
    Transplantation; 2004 Apr; 77(8):1154-62. PubMed ID: 15114077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of low dose cyclosporine and sirolimus on hepatic drug metabolism in the rat1.
    Bai S; Brunner LJ; Stepkowski SM; Napoli KL; Kahan BD
    Transplantation; 2001 Jun; 71(11):1585-92. PubMed ID: 11435969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function.
    Russ G; Segoloni G; Oberbauer R; Legendre C; Mota A; Eris J; Grinyó JM; Friend P; Lawen J; Hartmann A; Schena FP; Lelong M; Burke JT; Neylan JF;
    Transplantation; 2005 Nov; 80(9):1204-11. PubMed ID: 16314787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506.
    Andoh TF; Burdmann EA; Fransechini N; Houghton DC; Bennett WM
    Kidney Int; 1996 Oct; 50(4):1110-7. PubMed ID: 8887267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunosuppressive treatment and progression of histologic lesions in kidney allografts.
    Morales JM
    Kidney Int Suppl; 2005 Dec; (99):S124-30. PubMed ID: 16336565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity.
    Shihab FS; Bennett WM; Yi H; Choi SO; Andoh TF
    Kidney Int; 2004 Apr; 65(4):1262-71. PubMed ID: 15086465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus and sirolimus in combination with cyclosporine have different effects on renal metabolism in the rat.
    Bohra R; Schöning W; Klawitter J; Brunner N; Schmitz V; Shokati T; Lawrence R; Arbelaez MF; Schniedewind B; Christians U; Klawitter J
    PLoS One; 2012; 7(10):e48063. PubMed ID: 23118926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of cyclosporine, tacrolimus and sirolimus on vascular changes related to immune response.
    Rigol M; Solanes N; Sionis A; Gálvez C; Martorell J; Rojo I; Brunet M; Ramírez J; Roqué M; Roig E; Pérez-Villa F; Barquín L; Pomar JL; Sanz G; Heras M
    J Heart Lung Transplant; 2008 Apr; 27(4):416-22. PubMed ID: 18374878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional haemodynamic effects of cyclosporine A, tacrolimus and sirolimus in conscious rats.
    Gardiner SM; March JE; Kemp PA; Fallgren B; Bennett T
    Br J Pharmacol; 2004 Feb; 141(4):634-43. PubMed ID: 14744807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of early and late conversion of sirolimus in experimental model of chronic cyclosporine nephropathy.
    Kim JY; Ghee JY; Lim SW; Piao SG; Chung BH; Yoon HE; Hwang HS; Choi BS; Kim J; Yang CW
    J Korean Med Sci; 2012 Feb; 27(2):160-9. PubMed ID: 22323863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of sirolimus alone or in combination with cyclosporine A on renal ischemia/reperfusion injury.
    Pereira BJ; Castro I; Burdmann EA; Malheiros DM; Yu L
    Braz J Med Biol Res; 2010 Aug; 43(8):737-44. PubMed ID: 20549136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressant use without bone loss--implications for bone loss after transplantation.
    Goodman GR; Dissanayake IR; Sodam BR; Gorodetsky E; Lu J; Ma YF; Jee WS; Epstein S
    J Bone Miner Res; 2001 Jan; 16(1):72-8. PubMed ID: 11149492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study.
    Ekberg H; Bernasconi C; Nöldeke J; Yussim A; Mjörnstedt L; Erken U; Ketteler M; Navrátil P
    Nephrol Dial Transplant; 2010 Jun; 25(6):2004-10. PubMed ID: 20106825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug interaction between cyclosporine and mTOR inhibitors in experimental model of chronic cyclosporine nephrotoxicity and pancreatic islet dysfunction.
    Piao SG; Bae SK; Lim SW; Song JH; Chung BH; Choi BS; Yang CW
    Transplantation; 2012 Feb; 93(4):383-9. PubMed ID: 22267156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.